Veritas In Silico Inc. was listed on the Tokyo Stock Exchange Growth Market (Ticker Code: 130A).
We would like to express our heartfelt gratitude to all our stakeholders who have supported us since our establishment.

Our corporate philosophy is to build a warm society where every patient, especially those with diseases that currently have no satisfactory treatment, can look forward to a brighter future, through our platform for mRNA-targeted small molecule drug discovery, which we provide to multiple pharmaceutical companies to jointly create innovative drugs.

We believe that mRNA-targeted small molecule drug discovery is a powerful approach that can address the medical needs of patients, as it can be applied to various diseases against which conventional protein-targeted drug discovery approaches are ineffective. We are also convinced that it is imperative to create small molecule drugs that have low manufacturing costs and are easy to store and transport in order to provide drugs to patients around the world.

We plan to advance our platform business for the discovery of mRNA-targeted small molecule drugs, as well as expand into a hybrid business that will involve the creation of internal drug pipelines. We also plan to diversify our business through other mRNA-related drug discoveries such as antisense oligonucleotides, a type of nucleic acid drug. Through these business expansion strategies, we will strive to maximize the value for all our stakeholders and contribute to the realization of a warm society in which patients with any disease can receive the best treatment.

We look forward to your continued warm support.